logo-loader
viewMaxCyte Inc

CRISPR Therapeutics to use MaxCyte’s technology in its search for cancer gene therapies

CRISPR will use MaxCyte’s Flow Electroporation technology to deliver its components into T-cells, which are known to attack the body’s own cells that have been infected by viruses

gene editing
Today’s agreement expands the pair’s existing relationship

MaxCyte Inc’s (LON:MXCT) Flow Electroporation technology will be used by CRISPR Therapeutics as part of its quest to develop new gene therapies for the treatment of cancer after the pair signed a commercial licence agreement.

Doug Doerfler, MaxCyte chief executive, said the agreement was a “validation” of his firm’s technology, while CRISPR boss, Samarth Kulkarni, said he was pleased to have secured access to “the leading ex vivo delivery platform for both clinical and commercial use”.

READ: MaxCyte on track to start first-ever clinical trial before year-end

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

In this case, CRISPR will use the technology to deliver its components into T-cells which attack the body’s own cells that have been invaded by viruses or bacteria.

Today’s (Friday’s) tie-up expands the relationship between MaxCyte and CRISPR. The two signed a deal last year which allowed the latter to use Flow Electroporation as part of its efforts to develop treatments for haemoglobin-related diseases.

In return for supplying its technology, MaxCyte will receive milestone and sales-based payments in addition to other licensing fees.

“The expansion of our relationship with CRISPR Therapeutics signifies a key milestone for MaxCyte and our technology, providing further validation for the value and versatility of our technology as a leading enabler of next-generation cell-based therapies," said MaxCyte President and CEO Doug Doerfler.

“CRISPR Therapeutics is a leader in gene editing, and we are very pleased to expand our collaboration into new therapeutic areas as we continue to explore the use of our technology to advance medicines to market that will make a difference for patients.”

Quick facts: MaxCyte Inc

Price: 110 GBX

AIM:MXCT
Market: AIM
Market Cap: £63.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read